Literature DB >> 23536533

Panel 5: Microbiology and immunology panel.

Timothy F Murphy1, Tasnee Chonmaitree, Stephen Barenkamp, Jennelle Kyd, Johanna Nokso-Koivisto, Janak A Patel, Terho Heikkinen, Noboru Yamanaka, Pearay Ogra, W Edward Swords, Tania Sih, Melinda M Pettigrew.   

Abstract

OBJECTIVE: The objective is to perform a comprehensive review of the literature from January 2007 through June 2011 on the virology, bacteriology, and immunology related to otitis media. DATA SOURCES: PubMed database of the National Library of Medicine. REVIEW
METHODS: Three subpanels with co-chairs comprising experts in the virology, bacteriology, and immunology of otitis media were formed. Each of the panels reviewed the literature in their respective fields and wrote draft reviews. The reviews were shared with all panel members, and a second draft was created. The entire panel met at the 10th International Symposium on Recent Advances in Otitis Media in June 2011 and discussed the review and refined the content further. A final draft was created, circulated, and approved by the panel.
CONCLUSION: Excellent progress has been made in the past 4 years in advancing an understanding of the microbiology and immunology of otitis media. Advances include laboratory-based basic studies, cell-based assays, work in animal models, and clinical studies. IMPLICATIONS FOR PRACTICE: The advances of the past 4 years formed the basis of a series of short-term and long-term research goals in an effort to guide the field. Accomplishing these goals will provide opportunities for the development of novel interventions, including new ways to better treat and prevent otitis media.

Entities:  

Mesh:

Year:  2013        PMID: 23536533      PMCID: PMC4021594          DOI: 10.1177/0194599812459636

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  272 in total

1.  Genome analysis of Moraxella catarrhalis strain BBH18, [corrected] a human respiratory tract pathogen.

Authors:  Stefan P W de Vries; Sacha A F T van Hijum; Wolfgang Schueler; Kristian Riesbeck; John P Hays; Peter W M Hermans; Hester J Bootsma
Journal:  J Bacteriol       Date:  2010-05-07       Impact factor: 3.490

2.  Survival of bacterial biofilms within neutrophil extracellular traps promotes nontypeable Haemophilus influenzae persistence in the chinchilla model for otitis media.

Authors:  Wenzhou Hong; Richard A Juneau; Bing Pang; W Edward Swords
Journal:  J Innate Immun       Date:  2009-02-27       Impact factor: 7.349

3.  Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial.

Authors:  Santtu Heinonen; Heli Silvennoinen; Pasi Lehtinen; Raija Vainionpää; Tero Vahlberg; Thedi Ziegler; Niina Ikonen; Tuomo Puhakka; Terho Heikkinen
Journal:  Clin Infect Dis       Date:  2010-10-15       Impact factor: 9.079

Review 4.  Haemophilus influenzae and the complement system.

Authors:  Teresia Hallström; Kristian Riesbeck
Journal:  Trends Microbiol       Date:  2010-06       Impact factor: 17.079

5.  TLR-9, NOD-1, NOD-2, RIG-I and immunoglobulins in recurrent otitis media with effusion.

Authors:  Myung Gu Kim; Dong Choon Park; Ju Sup Shim; Hoon Jung; Moon Suh Park; Young Il Kim; Jin Woo Lee; Seung Geun Yeo
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-10-25       Impact factor: 1.675

6.  The inverse correlation between Staphylococcus aureus and Streptococcus pneumoniae colonization in infants is not explained by differences in serum antibody levels in the Generation R Study.

Authors:  Ankie Lebon; Nelianne J Verkaik; Corné P de Vogel; Herbert Hooijkaas; Henri A Verbrugh; Willem J B van Wamel; Vincent W V Jaddoe; Albert Hofman; Peter W M Hermans; Tim J Mitchell; Henriette A Moll; Alex van Belkum
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

7.  Binding of complement regulators to invasive nontypeable Haemophilus influenzae isolates is not increased compared to nasopharyngeal isolates, but serum resistance is linked to disease severity.

Authors:  Teresia Hallström; Fredrik Resman; Mikael Ristovski; Kristian Riesbeck
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

8.  The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms.

Authors:  Catherine Hyams; Emilie Camberlein; Jonathan M Cohen; Katie Bax; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

9.  A unique glycosyltransferase involved in the initial assembly of Moraxella catarrhalis lipooligosaccharides.

Authors:  Johanna M Schwingel; Frank St Michael; Andrew D Cox; Hussein Masoud; James C Richards; Anthony A Campagnari
Journal:  Glycobiology       Date:  2008-03-12       Impact factor: 4.313

10.  Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related.

Authors:  Monica Moschioni; Claudio Donati; Alessandro Muzzi; Vega Masignani; Stefano Censini; William P Hanage; Cynthia J Bishop; Joice Neves Reis; Staffan Normark; Birgitta Henriques-Normark; Antonello Covacci; Rino Rappuoli; Michèle A Barocchi
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

View more
  4 in total

Review 1.  Interaction Between Allergy and Middle Ear Infection.

Authors:  Jeong-Hoon Oh; Woo Jin Kim
Journal:  Curr Allergy Asthma Rep       Date:  2016-09       Impact factor: 4.806

Review 2.  Update on otitis media - prevention and treatment.

Authors:  Ali Qureishi; Yan Lee; Katherine Belfield; John P Birchall; Matija Daniel
Journal:  Infect Drug Resist       Date:  2014-01-10       Impact factor: 4.003

Review 3.  Subversion of host immune responses by otopathogens during otitis media.

Authors:  James M Parrish; Manasi Soni; Rahul Mittal
Journal:  J Leukoc Biol       Date:  2019-05-10       Impact factor: 4.962

Review 4.  Otitis media.

Authors:  Anne G M Schilder; Tasnee Chonmaitree; Allan W Cripps; Richard M Rosenfeld; Margaretha L Casselbrant; Mark P Haggard; Roderick P Venekamp
Journal:  Nat Rev Dis Primers       Date:  2016-09-08       Impact factor: 52.329

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.